XAGE

XAGE is a $644K micro-cap trading at $0.26 on the OTCQB after Nasdaq delisted its securities on September 12, 2025 for failing minimum bid-price and equity rules. The 10-K carries an explicit going-concern warning: management states negative net working capital of $5.97M, a net loss from continuing operations of $6.91M, and negative operating cash flow of $3.33M raise 'substantial doubt about our ability to continue as a going concern within one year.' Stockholders' equity is negative $5.87M against $8.23M of liabilities (of which $7.92M is current) versus only $707K of cash — the balance sheet is insolvent and survival depends entirely on raising new capital, which management concedes has 'no guarantees.'

The headline +3,701% revenue growth to $1.91M is an accounting artifact of the January 2025 Elevai skincare acquisition, not organic demand — the filing confirms 'Elevai Skincare's skincare and haircare products generated revenue of approximately $1.89 million in 2025,' meaning essentially all revenue is one acquired product line off a near-zero base ($50K in FY2024). Even so, operating expenses of $8.2M dwarf $1.09M of gross profit, producing a -371.6% operating margin. A retained deficit of $75.8M and cumulative losses every year since FY2021 show a company that has never demonstrated a path to profitability.